Aclaris Therapeutics Shares Spike Higher; Piper Sandler Upgrads Stock To Overweight With $13 Target Following Biosion Deal; Highlights Pipeline For Atopic Dermatitis And I&I Market, Catalysts Expected In 2025 Trials
Aclaris Therapeutics Shares Spike Higher; Piper Sandler Upgrads Stock To Overweight With $13 Target Following Biosion Deal; Highlights Pipeline For Atopic Dermatitis And I&I Market, Catalysts Expected In 2025 Trials
aclaris therapeutics股價大漲；派傑投資將股票評級提升至超配，目標價13美元，此舉是基於與Biosion達成協議；重點在特應性皮炎和I＆I市場的產品線，預計2025年有重大進展試驗。
Aclaris Therapeutics Shares Spike Higher; Piper Sandler Upgrads Stock To Overweight With $13 Target Following Biosion Deal; Highlights Pipeline For Atopic Dermatitis And I&I Market, Catalysts Expected In 2025 Trials
Aclaris Therapeutics股價飆升；派珀·桑德勒在Biosion交易後將股票上調至增持，目標爲13美元；重點介紹特應性皮炎和I&I市場的管道，預計將在2025年進行試驗的催化劑
資訊熱榜
更新時間